| Prev Close | 86.44 |
| Open | 86.92 |
| Day Low/High | 86.21 / 86.95 |
| 52 Wk Low/High | 62.66 / 92.99 |
| Volume | 7.82M |
| Avg Volume | 7.67M |
AbbVie Inc. (ABBV)
86.74
0.30
0.35
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.48B |
| Market Cap | 127.83B |
| EPS | 3.70 |
| P/E Ratio | 37.91 |
| Div & Yield | 4.72 (4.92%) |
Activating My Dip-Buying Shopping List
I added to two positions Tuesday, as growth catalysts are in play this earnings season.
These 2 Biotech Stocks Still Have Upside
The biotech sector has seen a big rally, but there are still opportunities.
AbbVie Could Climb Even Higher
AbbVie prices are way above the rising 50-day moving average line.
Dollar Traders Believe What They See, Not What They Hear: Market Recon
Currency traders see the Trump administration boosting manufacturing via a weak dollar.
Jim Cramer: The 3 Best Sectors That Lifted the Stock Market
It's hard to understand the magnitude of the change.
Stop Worrying About Valuations After Amazon, Alphabet and Microsoft's Earnings
The revenue and profit gains from some of the biggest technology companies like Amazon AMZN, Alphabet GOOGL and Microsoft MSFT show that valuations aren't so stretched.
There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon
The ECB's super dovish message was good for the markets.
Alphabet, Amazon and Expedia: This Is What You Must Know on Friday
U.S. futures point a higher open following earnings beats from Amazon, Alphabet and Microsoft after the bell on Thursday.
AbbVie Is Likely to Correct: Book Some Profits
ABBV has gone 'vertical' on the daily chart.
These Stocks Are Ready to Reverse Course
This week's bullish and bearish reversal patterns.
AbbVie Reaches All-Time Highs
Today's breakout could carry the stock sharply higher.
Earnings: Assessing 3 Biotech Bellwethers
How did Celgene, AbbVie and Gilead fare last quarter?
Cramer: When Oil Falls, These Dominoes Get Hit
It doesn't look like Washington will be much help.
AbbVie Is Flexing Its Abs
ABBV is now set up well for more upside.
A Trio of Stocks Up on Nice Results
The market is off to a decent start as investors try to digest scores of first-quarter earnings reports. Bristol-Myers Squibb is just one of many large-cap drug and biotech companies reporting today. BMY shares are up as earnings and revenue easily ...
Early-Morning Earnings Extravaganza
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...
Surveying the NASH Drug Landscape
Biotech investors should keep a close eye on the progress in this huge potential market.
2 Biotech Pullback Targets
Acadia and Neurocrine both have catalysts for growth; buy any weakness.
Cramer: Stay the Course, but Keep Cash Handy
It's pretty normal to have profit-taking after such a strong first quarter.
Cramer: Buyers for Bristol-Myers Are Few and Far Between
Icahn may have a tough time finding interest in this behemoth.
Health Care ETF Has Been Ailing
You might want to review your holdings in the sector.
Streamlined FDA Approval Process Would Boost Drug Makers
Would get drugs to market faster and possibly more cheaply.
Novice Trade: AbbVie
Getting FDA to streamline its approval process would boost drug makers.
Trump Investing: Listen, Don't Overreact
Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.
Create a 'Barbell' of Value, Income Stocks
Value stocks will extend their outperformance over growth stocks that began last year.
What to Watch Friday: American Airlines Earnings, Fourth-Quarter GDP
On Friday, investors will get quarterly results from American Airlines and the release of fourth quarter gross domestic product.
Biotech Sector to See M&A, Earnings Action
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
Biotech Just Got Trumped
But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.
